Clinical trial
A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
NCT03051490 is registered in ClinicalTrials.gov with Anthera Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
- Lead sponsor
- Anthera Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- April 28, 2017
- Completion date
- June 30, 2018
- Enrollment
- 140 (estimated)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.